News, reviews and podcasts from annual scientific meetings and symposiums around the world.
ASH 2024: Longer-term data for asciminib reinforce superior efficacy with favourable safety and tolerability profile in adults with newly diagnosed CML
Novartis today announced positive, longer-term results from the pivotal Phase III ASC4FIRST trial with asciminib…